NCT06892678View on ClinicalTrials.gov

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
Osteosarcoma RecurrentEwing's Tumor Recurrent
Interventions
DRUG

DFMO

DFMO dose will be calculated based on the BSA measured within 14 days prior to the beginning of each cycle. Tablets may be swallowed whole, chewed, or crushed and mixed with soft food or liquid.

Trial Locations (1)

10467

RECRUITING

Montefiore Medical Center, The Bronx

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Montefiore Medical Center

OTHER